No One Owns Quantum Science: The First Principle of the International Year of Quantum
By Jenn Mullen
As we celebrate 2025—the International Year of Quantum (IYQ)—we embark on a journey through the eight guiding principles that have shaped a century of quantum discovery. This series begins with perhaps the most foundational principle: 'No one owns quantum science.'
The Declaration
The IYQ's official declaration of this principle states:
'No individual, society, country, institution, or discipline can claim ownership of the past or future of quantum science; it is knowledge that should be free to all. IYQ recognizes those who put effort into studying, developing, investigating, using, and teaching quantum science and technology, while seeking to solicit and answer questions from anyone who wants to learn more about it.'
This statement isn't merely aspirational—it reflects the very essence of how quantum mechanics emerged and continues to evolve. But what does it mean in practice, and why does it matter as we commemorate 100 years of quantum mechanics?
Born from Collective Genius
When we trace quantum science to its origins, we find not a single inventor but a tapestry of brilliant minds wrestling with the universe's most profound mysteries. In July 1925, Werner Heisenberg published his groundbreaking paper on quantum theoretical reinterpretation, followed shortly by the seminal " Three-Man Paper " with Max Born and Pascual Jordan that September. Yet these works didn't emerge from isolation.
They built upon the quantum theories of Max Planck and Albert Einstein's work on the photoelectric effect. They were influenced by Niels Bohr's atomic model and Louis de Broglie's matter waves. The mathematics drew from the work of numerous mathematicians across Europe. No single genius 'invented' quantum mechanics—it evolved through conversation, correspondence, and spirited debate among physicists from Germany, Denmark, Austria, France, the Netherlands, and beyond.
The famous Solvay Conferences, beginning in 1911, exemplified this spirit of international collaboration. Scientists gathered across national boundaries—sometimes even as their countries were in political conflict—to grapple with quantum's deepest questions. The iconic 1927 Fifth Solvay Conference photo captures this perfectly: 29 scientists from different countries and backgrounds united by a shared quest to understand the quantum world .
Today's Quantum Commons
A century later, this collaborative ethos thrives in initiatives like the European Quantum Flagship, the US National Quantum Initiative, China's national quantum projects, and international research partnerships that span continents. While nations may compete in quantum advancement, the underlying science remains part of our shared human heritage.
Modern quantum computing companies—despite operating in a competitive landscape—have fostered remarkable openness. Many maintain open-source tools and frameworks that invite global contribution. A number of companies and platforms provide cloud access to quantum processors, allowing researchers, educators, and curious minds worldwide to run quantum experiments without needing to build multi-million-dollar hardware.
Repositories of quantum algorithms and educational resources created by and for developers from every corner of the globe are widely available. Graduate students in Bangalore collaborate with professors in Berkeley. Researchers in Beijing build upon discoveries made in Boston. A high school student in rural areas can access the same quantum computing platforms as scientists at elite institutions.
Why It Matters
This principle—that no one owns quantum science—isn't merely philosophical; it's pragmatic. Quantum mechanics tackles questions so profound and complex that they require diverse perspectives. The field advances most rapidly when knowledge flows freely, when insights from condensed matter physics inform quantum computing, when theoretical mathematics inspires experimental breakthroughs.
As quantum technologies approach potential commercial applications—from secure communications to powerful computing paradigms and precise sensors—economic pressures might tempt some to enclose quantum knowledge behind proprietary walls. The IYQ's first principle reminds us that while specific implementations may be owned, the foundational science belongs to humanity.
This openness also ensures that quantum science doesn't become the exclusive domain of wealthy nations or institutions. When knowledge is freely shared, brilliant minds everywhere can contribute, regardless of geography or resources. Some of tomorrow's most transformative quantum breakthroughs may come from unexpected places if we maintain this commitment to open access.
The Centennial Invitation
As we mark the 100th anniversary of quantum mechanics' formalization, the principle that 'no one owns quantum science' serves as both a celebration of the field's collaborative history and a recommitment to its open future. It invites all of us—regardless of background—to engage with quantum concepts, to ask questions, to contribute where we can.
Whether you're a seasoned quantum physicist, a student just beginning to explore wave functions, or someone simply curious about the strange and beautiful rules that govern our reality at its smallest scales, the quantum world belongs to you too. That's the promise and the challenge of the International Year of Quantum's first principle: this revolutionary science—with all its wonder and potential—is our collective inheritance and responsibility.
In the coming weeks, we'll explore the remaining seven principles that guide the IYQ celebration, each illuminating different facets of quantum science's past, present, and promising future. For now, remember that quantum science has no single owner because it belongs to us all.
Learn with Keysight
Keysight is committed to empowering the next generation of engineers and innovators. Explore Learn to find a rich and growing library of resources spanning a range of technical areas, industries, and specialties. Explore Learn now .
_________________________________
This is the first in an eight-part series exploring the guiding principles of the 2025 International Year of Quantum. Next week: 'Everyone is invited—Making quantum science accessible to all.'
Visit 3BL Media to see more multimedia and stories from Keysight Technologies
Page 2
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Scientists unveil breakthrough drug that could halt and reverse deadly liver fibrosis
Liver fibrosis often develops without symptoms and has no approved cure. But researchers at the University of Sunderland have discovered a new enzyme-blocking treatment that could finally help stop or reverse the disease. Dr Maria Teresa Borrello and her team have found that blocking the enzyme HDAC6 with newly developed drugs could reduce liver scarring in people with fibrosis. HDAC6 plays a role in regulating inflammation and cellular stress, and the research suggests it also helps activate hepatic stellate cells, which are responsible for producing collagen, a major driver of scar tissue formation. Dr Borrello, who is a lecturer in Pharmaceutical and Medicinal Chemistry at the University, said her team has developed two new drugs specifically designed to block HDAC6 activity. 'So far, we've seen encouraging laboratory results showing that HDAC6 inhibitors – or blockers – reduce inflammation and cellular stress responses – both of which are key contributors to fibrosis, she said in a release. 'These findings support the idea that HDAC6 is a promising drug target for treating liver fibrosis. We are also starting to understand more about how these compounds work at the molecular level, which is essential for designing better, safer treatments.' The researchers hope their findings will form the basis of new treatments that can significantly improve the lives of people with this condition and potentially other inflammation-related diseases, including skin disorders. 'This research is a step forward in finding a treatment for liver fibrosis. Our HDAC6 inhibitors provide a more targeted approach and by focusing on a key cause of fibrosis, we may be able to stop the disease before it reaches irreversible stages,' Dr Borello said. 'By stopping or reversing the scarring process, we could reduce the need for liver transplants and improve long-term health outcomes.' Researchers believe that targeting the root cause of fibrosis could mark a turning point in the treatment of liver disease. As efforts to tackle chronic conditions evolve, such precision therapies could change how currently untreatable diseases are managed. The UK's leading liver health charity, the British Liver Trust, has welcomed the research findings. "Liver disease often develops without symptoms, and most people only learn they have liver damage when it's too late for effective treatment - usually limited to a liver transplant or lifestyle changes,' Pamela Healy OBE, Chief Executive at the Trust, said. 'While this new research is still in its early stages, it shows promise for developing treatments that could improve, and ultimately save, the lives of thousands affected by liver disease." Liver disease is responsible for approximately four percent of premature deaths globally, with liver fibrosis being one of its most serious and often undetected forms. In the UK alone, an estimated 2 million people are affected. The condition develops when long-term damage to the liver, commonly caused by alcohol use, obesity, or chronic infections, triggers the formation of scar tissue. As the scarring worsens over time, it can lead to life-threatening complications such as liver failure or cancer. Because symptoms often appear only in the advanced stages, many people are unaware they have the disease, and currently, there are no approved treatments to halt or reverse the scarring study has been published in The Febs Journal.
Associated Press
6 hours ago
- Associated Press
Sire Search Identifies Top 5 Platforms to Boost Biotech Career Growth
Hey, biotech folks! Whether you're a lab whiz itching to land your next role in drug discovery or a hiring manager hunting for the perfect candidate to boost your startup, the life sciences world is buzzing with potential. But, real talk—finding the right job or talent in this fast-moving industry can feel like trying to spot a single cell under a microscope. Overwhelming, right? That's were specialized recruitment websites swoop in like career superheroes. I've rounded up the five best platforms to help you navigate the biotech job maze, and guess what? SIRE Searchis leading the charge with its sharp, tailored approach. Let's dive in and see why these sites are your new allies for crushing it in biotech! 1. – Your Career's Guide A recruitment platform that feels like it knows you better than your lab partner. That's SIRE Searchin a nutshell. Based in Haarlem, Netherlands—a charming spot, by the way—SIRE has been shaking up the life sciences scene since 2012. Whether you're into pharmaceuticals, medical devices, or even fast-moving consumer goods (yep, they've got that covered), SIRE's the place to find your next career win. Their reverse recruitment approach is like a secret weapon. Instead of tossing a pile of job listings your way, they do the heavy lifting first. Using data and market insights, their team—packed with recruiters who actually get biotech—handpicks roles that match your skills and goals. One Trustpilot reviewer raved, 'SIRE landed me a job that's spot-on for my expertise. They were quick and genuinely cared!' With a 4-star rating, they're clearly hitting the mark. 2. – The U.S. Biotech Hub Let's zip over to the States for BioSpace, a heavyweight for biotech and pharma jobs. With over 4,000 active listings, this sites like a treasure chest for anyone looking to dive into or climb higher in the U.S. biotech scene. From lab techs to execs, BioSpace has roles for every step of your journey. What's the deal with BioSpace? It's more than a job board—it's a whole community. You can narrow down searches by niche (like gene therapy or clinical trials) or location, so you're not stuck scrolling through irrelevant posts. They also dish out extras like industry updates, career tips, and their 'Best Places to Work' report, which is like a VIP list for biotech companies. The downside? It's mostly U.S.-focused, so it doesn't have SIRE's global reach. But for North American job seekers, BioSpace is a goldmine. 3. – Your Global Career Connector Dreaming of a biotech career that takes you worldwide? Meet Preclinical. With offices in places like the UK, Singapore, and the U.S., this platform hooks up candidates with roles in everything from drug development to regulatory affairs. It's like having a friend who knows the hottest jobs on every continent. Proclinical's strength is precision. Their recruiters dig into what employers need—skills, culture, the whole package—and match that with a huge candidate network. It's like they're playing career matchmaker, and they're good at it. They don't have SIRE's data-driven reverse recruitment trick, but their global scope is a big win for anyone wanting to think beyond borders. Plus, their blog's full of practical tips, like how to tweak your CV or nail an interview, which is super handy. 4. – The Science Lover's Hangout Next up is New Scientist Jobs, the friendly, all-purpose spot for science buffs. It covers a range of fields, but its biotech section is packed with roles in areas like vaccine research or molecular biology. Whether you're in Europe, the U.S., or elsewhere, this platform's global vibe makes it a welcoming place to explore. Why's it worth your time? It's easy to navigate, with filters to zero in on jobs by expertise or location. Their blog's a gem, too, with career advice and industry scoops that keep you in the loop. It's not as biotech-focused as SIRE, so you might need to sift a bit to find the right role. But if you're curious and love poking around, New Scientist Jobs is a solid bet. 5. – The Job-Finding Shortcut Last up is BioPharmGuy, the quirky underdog we're rooting for. Instead of hosting job listings, it points you straight to biotech company career pages, helping you dodge crowded job boards and find hidden opportunities. It's like a map of buried treasure. You can search by region or niche—like cell therapy or diagnostics—which makes it easy to target your sweet spot. The catch? It's more of a DIY experience, so you won't get the hands-on support you'd find with SIRE's recruiters. But for those who enjoy a bit of career sleuthing, BioPharmGuy is a clever tool to stand out. Why SIRE Search Takes the Crown? Let's give a shoutout to SIRE Searchfor stealing the show. Their reverse recruitment strategy is like having a career coach who's always one step ahead. By tapping into data and market trends, they find roles that fit you like a perfectly calibrated pipette. Their recruiters are biotech enthusiasts who speak your language and genuinely care about your next step. SIRE's focus on Europe—where biotech is thriving—gives them the edge, with connections to everyone from tiny startups to massive corporations. One candidate on Trustpilot said, 'SIRE made my job search feel effortless. They found me a role that's exactly where I want to be.' Employers love them, too, thanks to their knack for delivering candidates who nail both the skills and the vibe. Whether you're after a temp role or a corner office, SIRE's your partner in crime. 5 Tips to Nail Your Biotech Job Hunt Ready to hit these websites and land your dream role? Here's how to make it happen: Let's Wrap It Up The biotech world is full of possibilities, and these websites are your key to unlocking them. SIRE Searchleads the pack with its smart, personalized approach and deep love for life sciences. BioSpace, Preclinical, New Scientist Jobs, and BioPharmGuy are also stellar, each bringing their spark to the table. So, spruce up that resume, dive into these platforms, and get ready to make waves in biotech. Your next big opportunity is out there—grab it! Media Contact Company Name: Sire Search Email: Send Email Address:Staten Bolwerk City: 12011 MK Haarlem Country: Netherlands Website: Press Release Distributed by To view the original version on ABNewswire visit: Sire Search Identifies Top 5 Platforms to Boost Biotech Career Growth
Medscape
12 hours ago
- Medscape
Sibeprenlimab Halves uPCR in IgA Nephropathy Trial
VIENNA — Sibeprenlimab, a novel selective immune antibody, reduced the urine protein-to-creatinine ratio (uPCR) by more than half in patients with immunoglobulin A (IgA) nephropathy, according to an interim analysis of the VISIONARY trial. Beyond this clinical effect, a notable observation was the lack of safety concerns, especially given that, although sibeprenlimab is a selective agent, there may have been unexpected off-target effects. 'Safety's been a key consideration with these drugs,' study presenter Vlado Perkovic, MD, PhD, provost and scientia professor, University of New South Wales, Sydney, Australia, told Medscape Medical News . Sibeprenlimab represents a new mechanism of action and 'we don't yet fully understand the profile, so we've been looking at that data very carefully,' explained Perkovic. 'In particular, the infection risk has been my biggest concern, given we know that infections are dramatically increased in people with steroid therapy for example, in IgA nephropathy.' The results of the trial — the largest to date in the field — were presented at the 62nd European Renal Association Congress 2025 on June 6 and drew a warm applause from the audience. An Underestimated Condition IgA nephropathy is estimated to affect 2.5 per 100,000 people per year, although 'it's possible that that number is a significant underestimate,' said Perkovic. Diagnosis typically occurs between 20 and 40 years of age. And, despite supportive care, the majority of patients have a high lifetime risk of end-stage kidney disease (ESKD), with up to 50% of patients progressing to ESKD within 20 years of their clinical presentation. 'It's quite likely we've underestimated just how important this condition is,' said Perkovic, but 'we're fortunate that we're in the middle of something of a golden age of developing new treatments.' A number of therapies have been shown to reduce the risks associated with the disease, although they do not necessarily address the immunological basis of the condition. In addition to newer treatments, 'corticosteroids have long been used for people with IgA nephropathy,' Perkovic said, 'but of course, corticosteroids also have a range of different effects across the immune system,' which can lead to adverse outcomes. Sibeprenlimab is a selective IgG2 antibody that binds to and inhibits the biological activity of APRIL (a proliferation-inducing ligand), which is produced by mucosal epithelial and myeloid cells and binds to B cells. APRIL regulates B-cell-mediated immune responses and mediates IgG and IgA class switching in mature B cells. It is these two actions that make APRIL a key factor in the so-called 4-Hit process in the pathogenesis of IgA nephropathy, which results in the deposition of immune complexes in the glomerulus, leading to proteinuria and loss of kidney function. Phase 3 VISIONARY TRIAL Following on from the successful phase 2 ENVISION trial of sibeprenlimab, the researchers undertook the phase 3 VISIONARY trial, an ongoing study involving patients with biopsy-confirmed IgA nephropathy from 240 sites in 31 countries, who were randomized to sibeprenlimab or placebo for 100 weeks and followed up for a further 12 weeks. All patients were required to have a uPCR of ≥ 0.75 g/g or urine protein excretion of ≥ 1.0 g/day, an estimated glomerular filtration rate (eGFR) of ≥ 30 mL/min/1.73 m2, and to have been on a stable dose of either an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, with or without a SGLT2 inhibitor, for ≥ 3 months prior to screening. For the current pre-specified interim analysis, Perkovic reported the efficacy and safety results in the first 320 randomized patients (152 in the sibeprenlimab group and 168 in the placebo group), focusing on the primary endpoint of 24-hour uPCR at 9 months vs baseline, with eGFR and other data expected to be presented in 2026. The median age of the patients was 42-43 years. There were proportionally fewer females in the sibeprenlimab group (34.2%) vs the placebo group (40.5%). The majority of the patients were Asian, at 61.8% and 56.5%, respectively. Compared with a rise in uPCR at the 9-month follow-up in the placebo group, sibeprenlimab was associated with a 50.2% reduction in uPCR, giving a highly significant placebo-adjusted treatment effect of 51.2% ( P < .0001). Importantly, the benefit of sibeprenlimab on uPCR was seen as early as 4 weeks after initiating treatment and continued to accrue throughout follow-up. Ronald T. Gansevoort, MD, PhD, professor of medicine and a nephrologist at the Department of Nephrology, University Medical Center Groningen, Netherlands, who co-chaired the session, told Medscape Medical News that the results look 'very promising.' 'Recently, we have had several agents working in different ways that all show proteinuria lowering,' he continued, but the results from those studies show that the improvements seen in VISIONARY are 'the best proteinuria lowering' seen so far. Gansevoort noted, however, that this remains an interim analysis, and that he is really looking forward to seeing the kidney function results, adding: 'It was a little bit of a pity that they were not allowed to show at least the 9-month interim data on kidney function, which would have been so interesting.' Safety Results In terms of safety, the proportion of patients experiencing a treatment-related treatment-emergent adverse event (TEAE) was marginally lower with sibeprenlimab, at 32.9% vs 31.0% with placebo. The proportion of patients having a TEAE that led to treatment discontinuation was 0.7% vs 2.4%, respectively, and there were fewer severe and serious TEAEs with the experimental drug. 'If we focus on the infection-related adverse events,' Perkovic said, 'we can see that rates were numerically slightly higher in the sibeprenlimab than the placebo group, with a pattern that was broadly consistent, but with perhaps a slight excess of COVID 19.' He noted that this was 'the reverse of the pattern we've seen in the phase 2 trials, suggesting a chance' outcome. 'The data so far look remarkably encouraging,' he added. There's really no suggestion of an increased risk of infection,' with no opportunistic infections identified, 'and certainly no deaths.' More data is required from the ongoing follow-up to support what has been observed so far, but if the final results do bear out both the efficacy and safety outcome, it will show that sibeprenlimab is 'a precision approach to the fundamental abnormality in IgA nephropathy: that's the really exciting part,' said Perkovic. The study was funded by Otsuka Pharmaceutical Development and Commercialization. Perkovic declares relationships with Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Chinook Therapeutics, Eli Lilly & Company, Gilead Sciences, GlaxoSmithKline, Guard Therapeutics, Incyte, Janssen, Merck, Mitsubishi Tanabe Pharma, Mundipharma, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi, Shaanxi Micot Technology, Travere Therapeutics.
